Veronika E Izosimova, Natal'ja A Barmina, Marija P Zharikova, Oleg Y Alekseyev, Oxana A Ryzhkova, Marat H Sayfulin, Natal'ja A Popova, Mihail A Andreyev, Svetlana G Gagarina, Raisa M Rysdauletova, Natal'ja G Kamaeva, Anastasiya G Samoylova, Marija I Romanova
{"title":"重组人γ干扰素治疗结核病的临床多中心试验（GAM2022）","authors":"Veronika E Izosimova, Natal'ja A Barmina, Marija P Zharikova, Oleg Y Alekseyev, Oxana A Ryzhkova, Marat H Sayfulin, Natal'ja A Popova, Mihail A Andreyev, Svetlana G Gagarina, Raisa M Rysdauletova, Natal'ja G Kamaeva, Anastasiya G Samoylova, Marija I Romanova","doi":"10.2174/0118715265329137250102103507","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In this article, we present the results of a multicenter clinical trial of IFN-γ in patients with drug-susceptible and drug-resistant pulmonary Tuberculosis (TB) in routine clinical practice.</p><p><strong>Objective: </strong>This study aimed to confirm the efficacy and safety of IFN-γ administered to patients with TB.</p><p><strong>Methods: </strong>All patients were diagnosed with TB after being tested by bacterioscopic and molecular genetic methods and had no contraindications to standard chemotherapy.</p><p><strong>Results: </strong>Recombinant human IFN-γ proved high efficacy in multi-center clinical trial in routine TB practice.</p><p><strong>Conclusion: </strong>The results show that IFN-γ is efficient and safe in the treatment of pulmonary tuberculosis. Clinical Trial Registration #: NCT06118619.</p>","PeriodicalId":101326,"journal":{"name":"Infectious disorders drug targets","volume":" ","pages":"e18715265329137"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Clinical Multicenter Trial of Recombinant Human Interferon Gamma in Tuberculosis (GAM2022): Experience with the Use of Human Recombinant Interferon Gamma in TB Practice.\",\"authors\":\"Veronika E Izosimova, Natal'ja A Barmina, Marija P Zharikova, Oleg Y Alekseyev, Oxana A Ryzhkova, Marat H Sayfulin, Natal'ja A Popova, Mihail A Andreyev, Svetlana G Gagarina, Raisa M Rysdauletova, Natal'ja G Kamaeva, Anastasiya G Samoylova, Marija I Romanova\",\"doi\":\"10.2174/0118715265329137250102103507\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>In this article, we present the results of a multicenter clinical trial of IFN-γ in patients with drug-susceptible and drug-resistant pulmonary Tuberculosis (TB) in routine clinical practice.</p><p><strong>Objective: </strong>This study aimed to confirm the efficacy and safety of IFN-γ administered to patients with TB.</p><p><strong>Methods: </strong>All patients were diagnosed with TB after being tested by bacterioscopic and molecular genetic methods and had no contraindications to standard chemotherapy.</p><p><strong>Results: </strong>Recombinant human IFN-γ proved high efficacy in multi-center clinical trial in routine TB practice.</p><p><strong>Conclusion: </strong>The results show that IFN-γ is efficient and safe in the treatment of pulmonary tuberculosis. Clinical Trial Registration #: NCT06118619.</p>\",\"PeriodicalId\":101326,\"journal\":{\"name\":\"Infectious disorders drug targets\",\"volume\":\" \",\"pages\":\"e18715265329137\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious disorders drug targets\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0118715265329137250102103507\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118715265329137250102103507","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A Clinical Multicenter Trial of Recombinant Human Interferon Gamma in Tuberculosis (GAM2022): Experience with the Use of Human Recombinant Interferon Gamma in TB Practice.
Background: In this article, we present the results of a multicenter clinical trial of IFN-γ in patients with drug-susceptible and drug-resistant pulmonary Tuberculosis (TB) in routine clinical practice.
Objective: This study aimed to confirm the efficacy and safety of IFN-γ administered to patients with TB.
Methods: All patients were diagnosed with TB after being tested by bacterioscopic and molecular genetic methods and had no contraindications to standard chemotherapy.
Results: Recombinant human IFN-γ proved high efficacy in multi-center clinical trial in routine TB practice.
Conclusion: The results show that IFN-γ is efficient and safe in the treatment of pulmonary tuberculosis. Clinical Trial Registration #: NCT06118619.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
